重症患者液体平衡控制:POINCARE-2随机试验的按治疗分析结果
POINCARE-2试验的意向治疗分析对保守液体平衡策略降低重症患者死亡率的效果结论不明确。本研究为POINCARE-2的按治疗分析,纳入1361例≥18岁、机械通气且预计ICU停留>24小时的患者,基于偏离策略算法的程度计算暴露评分,评分≥75定义为暴露于策略。对照组24.8%、策略组69.4%的患者暴露评分≥75。实际暴露于POINCARE-2策略与60天全因死亡率无关(校正logistic回归OR 1.2,95%CI 0.85-1.55;工具变量logistic回归OR 1.0,95%CI 0.76-1.33)。
要点
- POINCARE-2策略包括每日称重持续14天,以及随后的液体摄入限制、利尿剂和/或超滤。
- 暴露评分≥75定义为实际暴露于策略;对照组24.8%、策略组69.4%的患者达到该评分。
- 实际暴露于策略与60天全因死亡率无关:校正logistic回归OR 1.2(95%CI 0.85-1.55),工具变量logistic回归OR 1.0(95%CI 0.76-1.33)。
- 纳入人群为≥18岁、机械通气且预计ICU停留>24小时的重症患者,共1361例。
- 该按治疗分析未能显示保守液体策略暴露带来生存获益。
适用人群与场景
- 年龄≥18岁、接受机械通气且预计ICU停留时间>24小时的重症患者。
诊断标准与关键阈值
- 暴露评分基于偏离POINCARE-2策略算法的程度计算,评分≥75定义为暴露于策略。
处置流程与药物剂量
- POINCARE-2策略包括每日称重持续14天,以及随后的液体摄入限制、利尿剂和/或超滤。
研究设计与关键结果
- 研究类型:POINCARE-2阶梯楔形随机对照试验的按治疗分析,共纳入1361例患者。
- 暴露情况:对照组24.8%的患者和策略组69.4%的患者暴露评分≥75。
- 主要终点:实际暴露于POINCARE-2策略与60天全因死亡率无关(校正logistic回归OR 1.2,95%CI 0.85-1.55;工具变量logistic回归OR 1.0,95%CI 0.76-1.33)。
- 缺失数据处理:采用多重插补。
证据类型、等级与局限
- 证据类型:随机对照试验的按治疗分析(二次分析)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论为实际暴露于POINCARE-2保守液体策略与重症患者死亡率降低无关,未据此给出推荐。
指南或共识出处
- POINCARE-2试验(ClinicalTrials.gov注册号NCT02765009,注册日期2016年4月29日)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Intention-to-treat analyses of POINCARE-2 trial led to inconclusive results regarding the effect of a conservative fluid balance strategy on mortality in critically ill patients. The present as-treated analysis aimed to assess the effectiveness of actual exposure to POINCARE-2 strategy on 60-day mortality in critically ill patients.
METHODS: POINCARE‑2 was a stepped wedge randomized controlled trial. Eligible patients were ≥ 18 years old, under mechanical ventilation and had an expected length of stay in ICU > 24 h. POINCARE-2 strategy consisted of daily weighing over 14 days, and subsequent restriction of fluid intake, administration of diuretics, and/or ultrafiltration. We computed a score of exposure to the strategy based on deviations from the strategy algorithm. We considered patients with a score ≥ 75 as exposed to the strategy. We used logistic regression adjusted for confounders (ALR) or for an instrumental variable (IVLR). We handled missing data using multiple imputations.
RESULTS: A total of 1361 patients were included. Overall, 24.8% of patients in the control group and 69.4% of patients in the strategy group had a score of exposure ≥ 75. Exposure to the POINCARE-2 strategy was not associated with 60-day all-cause mortality (ALR: OR 1.2, 95% CI 0.85-1.55; IVLR: OR 1.0, 95% CI 0.76-1.33).
CONCLUSION: Actual exposure to POINCARE-2 conservative strategy was not associated with reduced mortality in critically ill patients. Trial registration POINCARE-2 trial is registered at ClinicalTrials.gov (NCT02765009). Registered 29 April 2016.
参考来源
- Mansouri A, Buzzi M, Gibot S, et al. Fluid balance control in critically ill patients: results from as-treated analyses of POINCARE-2 randomized trial. Crit Care. 2023. PMID: 37932787. doi:10.1186/s13054-023-04701-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。